Drugs / CSPCHA115
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04161547 | Dec 2019 → Jun 2020 | asthma, nasal polyps, and aspirin intolerance | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-07-10 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA irasia.com ↗
THE GROUP’S INVESTIGATIONAL NEW DRUG “CSPCHA115” WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-10 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSPCHA115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04161547 ↗ |
| Route | Oral | “CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.” NCT04161547 ↗ |